Skip to main content
SpringerLink
Log in

31-Year-Old Female with Psoriasis on Adalimumab with Loss of Effect

  • Chapter
  • First Online:
Clinical Cases in Psoriasis

Part of the book series: Clinical Cases in Dermatology ((CLIDADE))

  • 497 Accesses

Abstract

A 31-year-old woman with a 5 pack-year smoking history presents with flare of psoriasis despite long-term efficacy of adalimumab and no change in compliance. Many commonly-utilized biologics, including adalimumab, may show diminished effectiveness of treatment due to development of anti-drug antibodies over time which may lower serum drug concentrations, and methotrexate may mediate clearance of these antibodies. Various triggers, such as psychosocial stress, smoking, alcohol use, and weight gain, may also mediate worsening of disease. The patient’s psoriasis cleared significantly after 3 months following addition of methotrexate to the regimen as well as reduction of smoking and stress.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease—algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51.

    Article  CAS  Google Scholar 

  2. Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.

    Article  CAS  Google Scholar 

  3. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):24–30.

    Article  CAS  Google Scholar 

  4. De Simone C, Caldarola G, Maiorino A, et al. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: a retrospective study. Dermatol Ther. 2016;29(5):372–6.

    Article  Google Scholar 

  5. Orlando A, Renna S, Rizzuto G, Orlando E, Affronti M, Cottone M. Selective use of combination therapy in patients with infliximab-resistant inflammatory bowel disease: data from a tertiary referral center. Clin Gastroenterol Hepatol. 2016;14(6):914.

    Article  Google Scholar 

  6. Sethu S, Govindappa K, Alhaidari M, et al. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp. 2012;60:331–44.

    Article  CAS  Google Scholar 

  7. Boehncke WH, Brembilla NC. Immunogenicity of biologic therapies: causes and consequences. Expert Rev Clin Immunol. 2018;14(6):513–23.

    Article  CAS  Google Scholar 

  8. Moots RJ, Xavier RM, Mok CC, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12(4):e0175207.

    Article  Google Scholar 

  9. Chiu HY, Chu TW, Cheng YP, Tsai TF. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. PLoS One. 2015;10(11):e0142930.

    Article  Google Scholar 

  10. Thomas LW, Lee EB, Wu JJ. Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. J Dermatol Treat. 2019;30(2):110–6.

    Article  CAS  Google Scholar 

  11. Jani M, Isaacs JD, Morgan AW, et al. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis. 2017;76(1):208–13.

    Article  CAS  Google Scholar 

  12. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–78.

    Article  CAS  Google Scholar 

  13. Farhangian ME, Feldman SR. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate. Am J Clin Dermatol. 2015;16(4):285–94.

    Article  Google Scholar 

  14. Dalaker M, Bonesrønning JH. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol. 2009;23(3):277–82.

    Article  CAS  Google Scholar 

  15. Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167(3):649–57.

    Article  CAS  Google Scholar 

  16. Philipp S, Wilsmann-Theis D, Weyergraf A, Rotterdam S, Frambach Y, Gerdes S. Combination of adalimumab with traditional systemic antipsoriatic drugs—a report of 39 cases. J Dtsch Dermatol Ges. 2012;10(11):821–37.

    PubMed  Google Scholar 

  17. Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213–22.

    Article  CAS  Google Scholar 

  18. Jayasekera PS, Parslew RA, Al-Sharqi A. Recapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab. JAAD Case Rep. 2016;2(4):310–4.

    Article  Google Scholar 

  19. Hackmon R, Sakaguchi S, Koren G. Effect of methotrexate treatment of ectopic pregnancy on subsequent pregnancy. Can Fam Physician. 2011;57(1):37–9.

    PubMed  PubMed Central  Google Scholar 

  20. Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):pii: E2297.

    Google Scholar 

  21. Bracke S, Lambert J. Viewpoint on handling anti-TNF failure in psoriasis. Arch Dermatol Res. 2013;305(10):945–50.

    Article  CAS  Google Scholar 

  22. Adışen E, Uzun S, Erduran F, Gürer MA. Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis. An Bras Dermatol. 2018;93(2):205–11.

    Article  Google Scholar 

  23. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25(6):606–15.

    Article  Google Scholar 

  24. Berg M, Svensson M, Brandberg M, Nordlind K. Psoriasis and stress: a prospective study. J Eur Acad Dermatol Venereol. 2008;22(6):670–4.

    Article  CAS  Google Scholar 

  25. Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(8):2011–9.

    Article  CAS  Google Scholar 

  26. Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133–9.

    Article  CAS  Google Scholar 

  27. Lombardi G, Perego S, Sansoni V, Diani M, Banfi G, Altomare G. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. BMJ Open. 2016;6(12):e011941.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical College of Georgia, Augusta University, Augusta, GA, USA

    Deeti J. Pithadia

  2. University of Cincinnati, College of Medicine, Cincinnati, OH, USA

    Kelly A. Reynolds

  3. Founder and CEO, Dermatology Research and Education Foundation, Irvine, CA, USA

    Jashin J. Wu

Authors
  1. Deeti J. Pithadia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly A. Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jashin J. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Founder and CEO, Dermatology Research and Education Foundation, Irvine, CA, USA

    Jashin J. Wu

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pithadia, D.J., Reynolds, K.A., Wu, J.J. (2019). 31-Year-Old Female with Psoriasis on Adalimumab with Loss of Effect. In: Wu, J. (eds) Clinical Cases in Psoriasis. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-18772-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18772-9_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18771-2

  • Online ISBN: 978-3-030-18772-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation